Eicosanoid-Regulated Myeloid ENaC and Isolevuglandin Formation in Human Salt-Sensitive Hypertension.

antigen-presenting cells cytochromes epithelial sodium channel hypertension isolevuglandin

Journal

Hypertension (Dallas, Tex. : 1979)
ISSN: 1524-4563
Titre abrégé: Hypertension
Pays: United States
ID NLM: 7906255

Informations de publication

Date de publication:
07 Sep 2023
Historique:
medline: 7 9 2023
pubmed: 7 9 2023
entrez: 7 9 2023
Statut: aheadofprint

Résumé

The mechanisms by which salt increases blood pressure in people with salt sensitivity remain unclear. Our previous studies found that high sodium enters antigen-presenting cells (APCs) via the epithelial sodium channel and leads to the production of isolevuglandins and hypertension. In the current mechanistic clinical study, we hypothesized that epithelial sodium channel-dependent isolevuglandin-adduct formation in APCs is regulated by epoxyeicosatrienoic acids (EETs) and leads to salt-sensitive hypertension in humans. Salt sensitivity was assessed in 19 hypertensive subjects using an inpatient salt loading and depletion protocol. Isolevuglandin-adduct accumulation in APCs was analyzed using flow cytometry. Gene expression in APCs was analyzed using cellular indexing of transcriptomes and epitopes by sequencing analysis of blood mononuclear cells. Plasma and urine EETs were measured using liquid chromatography-mass spectrometry. Baseline isolevuglandin Isolevuglandin formation in APCs responds to acute changes in salt intake in salt-sensitive but not salt-resistant people with hypertension, and this may be regulated by renal EET 14-15. Baseline levels of isolevuglandin

Sections du résumé

BACKGROUND BACKGROUND
The mechanisms by which salt increases blood pressure in people with salt sensitivity remain unclear. Our previous studies found that high sodium enters antigen-presenting cells (APCs) via the epithelial sodium channel and leads to the production of isolevuglandins and hypertension. In the current mechanistic clinical study, we hypothesized that epithelial sodium channel-dependent isolevuglandin-adduct formation in APCs is regulated by epoxyeicosatrienoic acids (EETs) and leads to salt-sensitive hypertension in humans.
METHODS METHODS
Salt sensitivity was assessed in 19 hypertensive subjects using an inpatient salt loading and depletion protocol. Isolevuglandin-adduct accumulation in APCs was analyzed using flow cytometry. Gene expression in APCs was analyzed using cellular indexing of transcriptomes and epitopes by sequencing analysis of blood mononuclear cells. Plasma and urine EETs were measured using liquid chromatography-mass spectrometry.
RESULTS RESULTS
Baseline isolevuglandin
CONCLUSIONS CONCLUSIONS
Isolevuglandin formation in APCs responds to acute changes in salt intake in salt-sensitive but not salt-resistant people with hypertension, and this may be regulated by renal EET 14-15. Baseline levels of isolevuglandin

Identifiants

pubmed: 37675576
doi: 10.1161/HYPERTENSIONAHA.123.21285
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Lale A Ertuglu (LA)

Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN. (L.A.E., T.A.I.).

Ashley Pitzer Mutchler (A)

Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN. (A.P.M., S.J., C.L.L., F.E., M.S., D.J.B., D.O.K., C.L.E., B.C.K., A.K.).

S Jamison (S)

Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN. (A.P.M., S.J., C.L.L., F.E., M.S., D.J.B., D.O.K., C.L.E., B.C.K., A.K.).
Meharry Medical College Nashville, TN (S.J.).

Cheryl L Laffer (CL)

Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN. (A.P.M., S.J., C.L.L., F.E., M.S., D.J.B., D.O.K., C.L.E., B.C.K., A.K.).

Fernando Elijovich (F)

Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN. (A.P.M., S.J., C.L.L., F.E., M.S., D.J.B., D.O.K., C.L.E., B.C.K., A.K.).

Mohammad Saleem (M)

Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN. (A.P.M., S.J., C.L.L., F.E., M.S., D.J.B., D.O.K., C.L.E., B.C.K., A.K.).

Daniel J Blackwell (DJ)

Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN. (A.P.M., S.J., C.L.L., F.E., M.S., D.J.B., D.O.K., C.L.E., B.C.K., A.K.).

Dmytro O Kryshtal (DO)

Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN. (A.P.M., S.J., C.L.L., F.E., M.S., D.J.B., D.O.K., C.L.E., B.C.K., A.K.).

Christian L Egly (CL)

Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN. (A.P.M., S.J., C.L.L., F.E., M.S., D.J.B., D.O.K., C.L.E., B.C.K., A.K.).

Melis Sahinoz (M)

Department of Medicine, Vanderbilt University Medical Center, Nashville, TN. (M.S.).

Quanhu Sheng (Q)

Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN. (Q.S.).

Celestine N Wanjalla (CN)

Division of Infectious Diseases, Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN. (C.N.W., S.P.).

Suman Pakala (S)

Division of Infectious Diseases, Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN. (C.N.W., S.P.).

Justin Yu (J)

Department of Biological Sciences, Vanderbilt University, Nashville, TN (J.Y.).

Orlando M Gutierrez (OM)

Division of Nephrology, Department of Medicine, University of Alabama at Birmingham (O.M.G.).

Thomas R Kleyman (TR)

Vanderbilt Center for Immunobiology (VCI) (T.R.K., A.K.).
Departments of Medicine, Cell Biology, Pharmacology, and Chemical Biology, University of Pittsburgh, PA (T.R.K., A.K.).

Björn C Knollmann (BC)

Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN. (A.P.M., S.J., C.L.L., F.E., M.S., D.J.B., D.O.K., C.L.E., B.C.K., A.K.).

T Alp Ikizler (TA)

Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN. (L.A.E., T.A.I.).

Annet Kirabo (A)

Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN. (A.P.M., S.J., C.L.L., F.E., M.S., D.J.B., D.O.K., C.L.E., B.C.K., A.K.).
Vanderbilt Center for Immunobiology (VCI) (T.R.K., A.K.).
Vanderbilt Institute for Infection, Immunology, and Inflammation (VI4) (A.K.).
Vanderbilt Institute for Global Health (VIGH) (A.K.).
Departments of Medicine, Cell Biology, Pharmacology, and Chemical Biology, University of Pittsburgh, PA (T.R.K., A.K.).

Classifications MeSH